Andrew Williamson
Insider
First SEC filing: April 6, 2026 · Latest: April 6, 2026
Insider at
Insider transactions
0 buys (P)
0 sells (S)
Net: $0
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| July 2, 2026 | EPSN | A | 7,803 | · | · | 199,276 Direct | +4.08% | Acquired | (price as of 2026-10-02) |
| July 2, 2026 | EPSN | A | 2,539 | · | · | 191,473 Direct | +1.34% | Acquired | (price as of 2026-10-02) |
| April 1, 2026 | EPSN | A | 2,540 | · | · | 188,934 Direct | +1.36% | Acquired | (price as of 2026-10-02) |
| March 31, 2026 | EPSN | F | 10,000 | $6.46 | $64,600 | 186,394 Direct | -5.09% | Disposed | -11.1% (price as of 2026-10-02) |
| Jan. 22, 2026 | EPSN | A | 71,130 | · | · | 196,394 Direct | +56.78% | Acquired | (price as of 2026-10-02) |
| Jan. 13, 2026 | EPSN | A | 8,315 | · | · | 125,264 Direct | +7.11% | Acquired | (price as of 2026-10-02) |
| Jan. 13, 2026 | EPSN | A | 15,092 | · | · | 116,949 Direct | +14.82% | Acquired | (price as of 2026-10-02) |
| Jan. 13, 2026 | EPSN | A | 2,541 | · | · | 101,857 Direct | +2.56% | Acquired | (price as of 2026-10-02) |
| Oct. 1, 2025 | EPSN | A | 2,541 | · | · | 99,316 Direct | +2.63% | Acquired | (price as of 2026-10-02) |
| Sept. 30, 2025 | EPSN | P | 12,500 | $4.94 | $61,750 | 72,500 Indirect | +20.83% | Acquired | 16.2% (price as of 2026-10-02) |
| Aug. 18, 2025 | EPSN | P | 10,000 | $5.64 | $56,400 | 60,000 Indirect | +20.00% | Acquired | 1.8% (price as of 2026-10-02) |
| July 1, 2025 | EPSN | A | 7,803 | · | · | 96,775 Direct | +8.77% | Acquired | (price as of 2026-10-02) |
| July 1, 2025 | EPSN | A | 2,541 | · | · | 88,972 Direct | +2.94% | Acquired | (price as of 2026-10-02) |
| April 1, 2025 | EPSN | A | 2,541 | · | · | 86,431 Direct | +3.03% | Acquired | (price as of 2026-10-02) |
| Feb. 3, 2025 | EPSN | A | 35,588 | · | · | 83,890 Direct | +73.68% | Acquired | (price as of 2026-10-02) |
| Jan. 6, 2025 | EPSN | A | 15,092 | · | · | 48,302 Direct | +45.44% | Acquired | (price as of 2026-10-02) |
| Jan. 6, 2025 | EPSN | A | 2,541 | · | · | 33,210 Direct | +8.29% | Acquired | (price as of 2026-10-02) |
| Oct. 1, 2024 | EPSN | A | 2,541 | · | · | 30,669 Direct | +9.03% | Acquired | (price as of 2026-10-02) |
| Sept. 18, 2024 | EPSN | P | 50,000 | $5.05 | $252,500 | 50,000 Indirect | · | Acquired | 13.7% (price as of 2026-10-02) |
| July 12, 2024 | EPSN | A | 7,803 | · | · | 28,128 Direct | +38.39% | Acquired | (price as of 2026-10-02) |
| July 12, 2024 | EPSN | A | 2,541 | · | · | 20,325 Direct | +14.29% | Acquired | (price as of 2026-10-02) |
| July 12, 2024 | EPSN | A | 7,803 | · | · | 38,128 Direct | +25.73% | Acquired | (price as of 2026-10-02) |
| July 12, 2024 | EPSN | A | 2,541 | · | · | 30,325 Direct | +9.15% | Acquired | (price as of 2026-10-02) |
| April 1, 2024 | EPSN | A | 2,540 | · | · | 17,694 Direct | +16.76% | Acquired | (price as of 2026-10-02) |
| Jan. 2, 2024 | EPSN | A | 2,540 | · | · | 15,244 Direct | +19.99% | Acquired | (price as of 2026-10-02) |
| Oct. 2, 2023 | EPSN | A | 2,541 | · | · | 12,704 Direct | +25.00% | Acquired | (price as of 2026-10-02) |
| July 4, 2023 | EPSN | A | 10,163 | · | · | 10,163 Direct | · | Acquired | (price as of 2026-10-02) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2023 | $239,000 | · | $355,006 | · | · | · | $12,448 | $744,454 |
| 2022 | $115,000 | · | $250,000 | · | · | · | $3,981 | $443,981 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.